Roche (OTCMKTS:RHHBY) Stock Passes Below 50-Day Moving Average – What’s Next?

by · The Cerbat Gem

Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $36.86 and traded as low as $34.71. Roche shares last traded at $35.00, with a volume of 970,153 shares.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RHHBY. Deutsche Bank Aktiengesellschaft downgraded Roche from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Bank of America raised Roche from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Our Latest Stock Report on Roche

Roche Price Performance

The company’s fifty day simple moving average is $36.78 and its 200 day simple moving average is $37.90.

Hedge Funds Weigh In On Roche

Institutional investors have recently bought and sold shares of the stock. Brooklyn Investment Group bought a new stake in Roche during the 3rd quarter valued at approximately $40,000. AlphaMark Advisors LLC purchased a new position in shares of Roche in the 3rd quarter valued at approximately $149,000. Archer Investment Corp boosted its position in shares of Roche by 10.6% during the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock valued at $236,000 after purchasing an additional 652 shares in the last quarter. IHT Wealth Management LLC purchased a new stake in Roche in the third quarter worth $236,000. Finally, Verity Asset Management Inc. bought a new position in Roche in the third quarter worth $253,000.

Roche Company Profile

(Get Free Report)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

Further Reading